• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Niagen Bioscience (NAGE) Gains Fresh Momentum, Is The Stock Still Cheap?

    Simply Wall St·08/08/2026 18:25:21
    Listen to the news

    Niagen Bioscience (NAGE) has moved back into the spotlight after two recent developments. A peer reviewed analysis highlighted Niagen supplementation’s impact on muscle epigenetic age acceleration, while Tru Niagen’s launch on Walmart.com expands its healthy aging reach.

    See our latest analysis for Niagen Bioscience.

    Recent announcements around Niagen Bioscience, including the peer reviewed muscle aging study and Tru Niagen’s Walmart.com debut, come after a challenging share price stretch. The stock is down 50.08% year to date on a share price return basis, while still showing a positive 3 year total shareholder return of 96.23%. This contrasts with a 1 year total shareholder return decline of 67.93%.

    If you want to see how other areas of the market are reacting to health science and aging themes, this is a good moment to check out 43 healthcare AI stocks

    For Niagen Bioscience, the steep share price reset sits alongside ongoing revenue and earnings, plus fresh scientific and retail milestones. Is this latest move really about the business, or about sentiment catching up with it, or lagging behind?

    Most Popular Narrative: 75.2% Undervalued

    Niagen Bioscience's most widely followed narrative places fair value at $12.60 per share, well above the last close of $3.12, which sets a clear valuation gap for investors to assess.

    Expansion into the pharmaceutical-grade Niagen ingredient market, including the launch of Niagen IV and injections at clinics, is expected to drive future revenue growth due to increasing demand and the anticipated resolution of supply chain issues. Continued e-commerce growth, supported by a significant increase in the Shopify platform's performance and a rising awareness of NAD-boosting products, suggests potential for further revenue growth and improved net margins due to the higher profitability of direct-to-consumer channels.

    Read the complete narrative.

    Want to see what sits behind that growth story and fair value gap? The narrative focuses on compounding revenue, rising margins and a richer earnings mix. Investors may wish to examine which assumptions have the greatest impact on the model.

    Result: Fair Value of $12.60 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the Niagen Bioscience story also carries real tension points, including ongoing regulatory and legal risks and the possibility that higher expenses could squeeze the expected margin profile.

    Find out about the key risks to this Niagen Bioscience narrative.

    Next Steps

    The mix of enthusiasm and caution around Niagen Bioscience is clear, so it makes sense to review the numbers and sentiment while this is fresh. To weigh both sides for yourself, start with the 2 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Niagen Bioscience?

    If you only focus on Niagen Bioscience, you could miss other opportunities where quality, price and resilience line up in your favour. Give yourself more options.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.